Skip to main content

Table 3 Outcomes of the febuxostat group and comparisons on the use of diuretics

From: Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort

  No diuretics
(n = 14 (42.4%))
Diuretics
(n = 19 (57.6%))
P
Primary outcome variable
 Maximum dose of febuxostat (mg/day) 80.0 (70.0–80.0) 80.0 (40.0–80.0) 0.398
Secondary outcome variables
 Baseline SU (mg/dL) 8.7 (7.6–9.6) 9.6 (8.0–11.4) 0.174
 Final SU (mg/dL) 3.5 (2.5–4.9) 3.9 (3.4–5.1) 0.439
 Final eGFR (ml/min) 49.1 (37.3–69.1) 30.5 (19.0–42–9) 0.004
 SU reduction (mg/dL) 5.0 (2.5–5.6) 4.5 (3.9–6.3) 0.733
 Achievement of SU targets
  - SU <6 mg/dl, n (%) 11 (78.6) 17 (81.0) 1.000
  - SU <5 mg/dl, n (%) 11 (78.6) 14 (66.7) 0.445
  - SU <4 mg/dl, n (%) 8 (57.1) 11 (52.4) 0.782
  1. Data shown as median (IQR) unless specified otherwise. In bold, statistically significant differences between subgroups. eGFR estimated glomerular filtration rate, SU serum urate